Tags: Drug.
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders such as systemic lupus erythematosus (SLE). The manufacturers in August 2009 announced success in early trials against SLE and the drug is in Phase III clinical trials as of February 2014.